Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Genomics, Proteomics, and Target Discovery

Abstract A208: Comparison of expression and function of two functional RARβ isoforms in human cancer: Clinical implications for the differential splicing of the RARβ gene

Catherine B. Swift, Victor A. Varela, Jason T. Graves, Ethan Dmitrovsky and W. Jeffrey Petty
Catherine B. Swift
1 Wake Forest University, Winston‐Salem, NC;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor A. Varela
1 Wake Forest University, Winston‐Salem, NC;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason T. Graves
1 Wake Forest University, Winston‐Salem, NC;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ethan Dmitrovsky
2 Dartmouth‐Hitchcock Medical Center, Lebanon, NH.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Jeffrey Petty
1 Wake Forest University, Winston‐Salem, NC;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-09-A208 Published December 2009
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA

Abstract

Purpose: Retinoids are derivatives of vitamin A that are used for treating and preventing certain cancers. Retinoid sensitivity in the lung is linked to expression of a specific isoform of the retinoic acid receptor β (RARβ), termed RARβ1′. This study compared the function of RARβ1′ and RARβ2 and assessed the expression of these isoforms in a panel of cancers. Experimental Design: RARβ1′ and RARβ2 were independently co‐transfected into BEAS‐2B human bronchial epithelial cells along with a retinoid responsive reporter plasmid. Transfectants were then treated with 4 µM all‐trans retinoic acid or control and reporter activation was measured. An isoform‐specific antibody for detection of RARβ1′ was also developed and validated. Using this antibody, RARβ1′ expression was evaluated by immunoblot analyses of normal lung versus lung cancer tissue specimens as well as in a panel of cancer cell lines including those of breast, colon, prostate, glioblastoma (GBM) and lung cancer origins. RARβ1′ expression was then examined in an extended panel of GBM cell lines. GBM cell lines were independently treated with 13‐cis‐retinoic acid, and growth assays and microarray analyses were each performed.

Results: In the absence of retinoid treatment, retinoid reporter activation was increased by co‐transfection of RARβ2 (P = .02) but not RARβ1′ (P = .21) in BEAS‐2B cells. When treated with the retinoid, transfection of either isoform enhanced reporter activation. RARβ1′ was noted to be expressed in normal lung tissue but absent in tumor tissue from patients with each of the common types of non‐small cell lung cancer. Analysis of multiple cancer cell lines revealed RARβ1′ expression only in the GBM cell lines. No appreciable expression was detected in the breast, colon, prostate, or lung cancer cell lines. Analysis of an extended panel of GBM cell lines revealed RARβ1′ expression in all examined GBM cell lines. The examined GBM cell lines were found to be sensitive to treatment with pharmacologically achievable dosages of 13‐cis retinoic acid. Microarray analyses revealed several novel candidate retinoid target genes activated in SNB‐19 GBM cells.

Conclusions: RARβ1′ and RARβ2 have differing effects on ligand‐independent signaling. RARβ1′ was repressed in all examined lung cancer cases and in most of the cancer cell lines studied. RARβ1′ protein was abundantly expressed in GBM cell lines which may help to explain the activity of 13‐cis retinoic acid for the treatment of GBM despite the modest single agent activity of retinoids for treating many epithelial cancers. Microarray data of GBM cells have uncovered several candidate retinoid‐target genes that may represent novel therapeutic targets.

Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A208.

  • Copyright © 2009, American Association for Cancer Research
Previous
Back to top
Molecular Cancer Therapeutics: 8 (12 Supplement)
December 2009
Volume 8, Issue 12 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A208: Comparison of expression and function of two functional RARβ isoforms in human cancer: Clinical implications for the differential splicing of the RARβ gene
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A208: Comparison of expression and function of two functional RARβ isoforms in human cancer: Clinical implications for the differential splicing of the RARβ gene
Catherine B. Swift, Victor A. Varela, Jason T. Graves, Ethan Dmitrovsky and W. Jeffrey Petty
Mol Cancer Ther December 10 2009 (8) (12 Supplement) A208; DOI: 10.1158/1535-7163.TARG-09-A208

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A208: Comparison of expression and function of two functional RARβ isoforms in human cancer: Clinical implications for the differential splicing of the RARβ gene
Catherine B. Swift, Victor A. Varela, Jason T. Graves, Ethan Dmitrovsky and W. Jeffrey Petty
Mol Cancer Ther December 10 2009 (8) (12 Supplement) A208; DOI: 10.1158/1535-7163.TARG-09-A208
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Genomics, Proteomics, and Target Discovery

  • Abstract PL02-03: The zinc-finger degrome
  • Abstract CN03-01: Functional genomics approaches to the discovery of paralog dependencies in cancer
  • Abstract CN03-02: Functional genomics approaches to identify targetable dependencies in cancer cells
Show more Genomics, Proteomics, and Target Discovery

Genomics, Proteomics, and Target Discovery: Poster Presentations

  • Abstract A201: Mutation profiling and prognostic value of BRAF, HRAS, KRAS, MET, NRAS, PIK3CA, KRASG12V in colon cancer: Results from NSABP C‐07
  • Abstract A209: Comprehensive analysis of the MET protooncogene promoter regulation
  • Abstract A202: RNAi as a tool to identify novel molecular vulnerabilities in myeloid leukemias
Show more Genomics, Proteomics, and Target Discovery: Poster Presentations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement